Skip to content

The Therapeutic Evaluation of Ultrasound-guided Transvaginal - cervical Microwave Ablation for Uterine Fibroids

The Therapeutic Evaluation of Ultrasound-guided Transvaginal - cervical Microwave Ablation for Uterine Fibroids

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17011910
Enrollment
Unknown
Registered
2017-07-08
Start date
2017-07-05
Completion date
Unknown
Last updated
2017-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine Fibroids

Interventions

experimental group:Ultrasound-guided Transvaginal - cervical Microwave Ablation for Uterine Fibroids
control group:Ultrasound guided percutaneous microwave ablation for uterine fibroids

Sponsors

The Second Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Patients are diagnosed with myoma by clinical symptoms and preoperative imaging and have surgical indications; 2. Intended to reserve uteri; 3. Patients are prepared to be treated by microwave ablation hysteromyoma under ultrasonic guidance; 4. Female patients with Childbearing or married childbearing age; 5. Patients are willing to cooperate with the follow-up and sign informed consent; 6. Patients are suitable for participating in this clinical trials considered by clinicians; 7. Patients have no serious visceral disease.

Exclusion criteria

Exclusion criteria: 1. Patients are unable to adhere to the follow-up?; 2. During the experiment, the experimenters are quit in various reasons; 3. Myoma is adjacent to the intestinal canal, bladder, large blood vessels and other important organs, and is not separated; 4. The diameter of submucosal myoma was < 2cm; Subserous myoma with titi, width < 3cm; 5. Combined with acute pelvic inflammation; 6. Severe coagulation dysfunction, liver, kidney and other important organ dysfunction; 7. Precancerous lesions and malignant neoplasms are not excluded; 8. Had received other local treatments, such as HIFU, RFA and UAE, 3 months before treatment, etc.

Design outcomes

Primary

MeasureTime frame
Change of uterine fibroids size;hemoglobin concentration;The related symptoms of uterine fibroids and health related life quality questionnaires were graded;Intraoperative and postoperative complications;

Countries

China

Contacts

Public ContactRen Qiongzhen

The Second Affiliated Hospital of Soochow University

renqiongzhen@163.com+86 13912646986

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026